Drug intelligence / Profile preview

cetuximab + dabrafenib + tislelizumab

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This specific three-drug combination therapy does not appear to exist based on available information. While cetuximab (EGFR inhibitor) and dabrafenib (BRAF inhibitor) have been studied together with trametinib for BRAF V600E mutant colorectal cancer, and tislelizumab (PD-1 inhibitor) has been approved for gastroesophageal cancers, there is no evidence of these three drugs being used together in a single regimen.

Targets

PDCD1 (Programmed cell death protein 1 receptor)EGFR T790M (Epidermal growth factor receptor T790M mutant)BRAF V600E

Beyond the preview

Go deeper on cetuximab + dabrafenib + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + dabrafenib + tislelizumab.

Explore the full profile